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ALTERED CIRCULATING FOLLICULAR HELPER T CELL PHENOTYPE IN 
SYSTEMIC LUPUS ERYTHEMATOSUS.  John H. Ho, Jin-Young Choi, and Joseph E. 
Craft.  Section of Rheumatology, Department of Internal Medicine, Yale University, 
School of Medicine, New Haven, CT 	   Autoreactive	  B	  cells	  in	  Systemic	  Lupus	  Erythematosus	  (SLE)	  undergo	  autoantigen	  selection,	  suggesting	  a	  requirement	  for	  germinal	  center	  follicular	  helper	  T	  (Tfh)	  cells	  in	  their	  maturation.	  	  However,	  evidence	  for	  dysregulation	  of	  Tfh	  cells	  in	  SLE	  and	  their	  contribution	  to	  disease	  activity	  remains	  unclear.	  	  Recently,	  blood	  CXCR5hi	  CD4	  T	  cells,	  a	  heterogeneous	  pool	  consisting	  of	  functionally	  distinct	  Th1-­‐,	  Th2-­‐,	  Th17-­‐like	  subsets,	  have	  been	  proposed	  to	  be	  the	  circulating	  counterpart	  of	  Tfh	  cells.	  	  The	  purpose	  of	  this	  study	  was	  to	  examine	  the	  hypothesis	  that	  Tfh	  dysregulation,	  as	  reflected	  in	  altered	  phenotype	  of	  blood	  CXCR5hi	  population,	  was	  associated	  with	  SLE	  disease	  activity.	  	  Blood	  samples	  from	  49	  clinically	  well-­‐characterized	  SLE	  patients,	  28 Behçet's disease (BD) patients as autoimmune disease 
control and 16 healthy controls were included.  Expression of key Tfh surface receptors 
(ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein-1) as well as 
composition of T helper subtypes within the circulating CXCR5hi compartment were 
enumerated by flow-cytometry.  The phenotype of blood CXCR5hi cells was correlated 
with clinical history and B cell phenotype.  SLE patients had significant expansion of 
circulating Tfh-like CD4 T cells (CXCR5hiICOShiPD-1hi) when compared to controls (p < 
0.001).  Interestingly, PD-1 mean florescence intensity (MFI) was markedly elevated in 
blood CXCR5hi subset of SLE patients when compared to controls (p < 0.001).  PD-1 
MFI in the CXCR5hi population correlated significantly with SLE disease activity index 
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(SLEDAI; Spearman r = 0.43, p = 0.03), blood plasmablast expansion (Spearman r = 
0.34, p = 0.02), and high anti-dsDNA antibody titers (p = 0.004).  Blood CXCR5hiPD-1hi 
cells phenotypically resembled pre- or post-germinal center Tfh cells, with increased 
percentage of IL-21 producers (p = 0.02), lower CCR7 MFI (p = 0.03) when compared to 
CXCR5hiPD-1lo subset, and low Bcl-6 expression.  Compared to BD patients, SLE 
patients had an increase in the CXCR5hi Th2 subset (p < 0.05) and a decrease in the Th17 
(p < 0.001) subsets. The expansion of the CXCR5hi Th2 subset was also positively 
associated with SLEDAI scores.  Our results demonstrate that altered phenotype and 
subset composition of blood Tfh-like cells is correlated with disease activity in lupus 
patients, suggesting a potential role of GC Tfh dysregulation in the pathogenesis of 
human SLE.
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune disease marked by 
immune complex-mediated tissue injury in multiple vital organs1.  The clinical 
manifestations and the underlying immunoregulatory factors that contribute to disease 
expression are diverse2.  Such heterogeneity poses a significant challenge for both 
clinical management and development of targeted therapeutics.  Thus, there is a need to 
identify the common pathogenic cellular pathway that leads to lupus disease activity in an 
effort to define rational therapeutic targets. 
The presence of autoantibodies is a common phenotype of SLE and their 
pathological role in lupus has been confirmed in animal models and clinical studies3.  The 
collaboration between germinal center (GC) CD4 T cells and B cells, via processes such 
as high-affinity B cell selection and B cell memory induction, is central to the production 
of autoantibodie4,5.  This is evidenced by the fact that pathogenic autoantibodies in SLE 
are high-affinity, somatically mutated, and Ig-switched antibodies that have undergone 
selection by T cells6-8.  In addition, spontaneous formation of GCs has been documented 
in a mouse model of SLE9.  Furthermore, intensive GC activity has been shown in 
patients with active lupus nephritis10.  Taken together, these data point to a vital role of 
GC T cells in the pathogenesis of SLE. 
Follicular helper T (Tfh) cells have been established as the specialized T cell 
subset responsible for the development of B cell response in the GC11.  Tfh cells are 
positioned in the B cell follicles of secondary lymphoid organs and are identified by a 
combination of cellular markers, including	  CXCR5,	  the	  chemokine	  receptor	  that	  enables	  the	  migration	  of	  Tfh	  cells	  toward	  B	  cell	  follicles12,13;	  ICOS,	  a	  co-­‐stimulatory	  
	   6	  
molecules	  important	  for	  the	  helper	  function	  of	  Tfh	  cells14;	  and	  PD1,	  a	  surface	  molecules	  classically	  known	  to	  provide	  inhibitory	  signals	  to	  the	  T	  cells15,	  but	  which	  also	  regulate	  GC	  B	  cell	  survival16.	  	  	  Functionally,	  Tfh	  cells	  also	  secrete	  key	  cytokines	  that	  promote	  growth,	  differentiation,	  and	  antibody	  class-­‐switching	  of	  B	  cells,	  such	  as	  IL-­‐4	  and	  IL-­‐2116-­‐18.	  	  Importantly,	  the	  expansion	  of	  Tfh	  cells	  is	  associated	  with	  the	  development	  of	  systemic	  autoimmunity	  in	  animal	  studies19,20.	  	  The	  expansion	  of	  Tfh	  cells	  has	  also	  been	  causally	  linked	  to	  the	  abundance	  of	  GCs,	  production	  of	  autoantibodies,	  and	  end-­‐organ	  damage	  in	  a	  mouse	  model	  of	  SLE21.	  	  Thus,	  in	  animal	  models	  of	  lupus,	  Tfh	  cells	  are	  centrally	  involved	  in	  the	  cellular	  pathway	  that	  lead	  to	  clinical	  disease.	  While	  the	  involvement	  of	  Tfh	  cells	  in	  animal	  models	  of	  SLE	  has	  been	  shown,	  evaluation	  of	  Tfh	  cells	  in	  human	  SLE	  has	  been	  limited	  by	  the	  inability	  to	  routinely	  study	  secondary	  lymphoid	  tissues	  in	  patients.	  	  Recently,	  however,	  studies	  have	  shown	  that	  circulating	  CXCR5hi	  CD4	  T	  cells	  are	  circulating	  counterparts	  of	  Tfh	  cells22.	  	  	  In	  ICOS-­‐	  and	  CD40L-­‐deficient	  patients,	  there	  are	  impaired	  GC	  formations	  and	  the	  absence	  of	  circulating	  CXCR5hi	  subset23.	  	  Conversely,	  expansion	  of	  blood	  CXCR5hi	  population	  has	  been	  noted	  post-­‐immunization	  in	  humans24.	  	  In	  another	  recent	  study,	  CXCR5hi	  subset	  is	  shown	  to	  efficiently	  induce	  naïve	  B	  cell	  differentiation	  and	  Ig	  type	  switch	  via	  secretion	  of	  key	  Tfh	  cytokines	  in	  vitro,	  demonstrating	  that	  they	  indeed	  share	  functional	  properties	  with	  Tfh	  cells25.	  	  Thus,	  blood	  CXCR5hi	  CD4	  T	  cells	  appears	  to	  be	  an	  attractive	  biomarker	  to	  study	  GC	  Tfh	  dysregulation	  in	  lupus.	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Recently,	  the	  expansion	  of	  blood	  CXCR5hiICOShi	  or	  CXCR5hiPD1hi	  subset	  has	  been	  found	  in	  a	  subset	  of	  SLE	  patients	  with	  severe	  end-­‐organ	  involvement26.	  	  However,	  the	  relationship	  between	  blood	  CXCR5hi	  population	  and	  SLE	  disease	  activity	  has	  not	  been	  demonstrated.	  	  In	  addition,	  CXCR5hi	  CD4	  T	  cells	  appear	  to	  be	  heterogeneous	  and	  can	  be	  functionally	  grouped	  into	  Th1-­‐,	  Th2-­‐,	  and	  Th17-­‐like	  cells25.	  	  Importantly,	  CXCR5hi	  Th2	  and	  Th17,	  but	  not	  Th1,	  subset	  have	  the	  capability	  to	  provide	  B	  cell	  help,	  and	  the	  skewed	  composition	  of	  CXCR5hi	  CD4	  T	  cell	  subsets	  may	  contribute	  to	  autoimmunity25.	  	  Whether	  the	  composition	  of	  blood	  CXCR5hi	  cells	  in	  human	  SLE	  is	  altered	  remains	  unknown.	  	  In	  an	  effort	  to	  elucidate	  the	  involvement	  of	  Tfh	  cells	  in	  SLE	  disease	  activity,	  we	  examined	  the	  surface	  phenotype	  and	  subset	  heterogeneity	  of	  blood	  CXCR5hi	  cells	  of	  SLE	  patients.	  	  	  We	  further	  correlated	  altered	  CXCR5hi	  cell	  phenotype	  with	  clinical	  history,	  SLE	  disease	  activity,	  and	  pathological	  B	  cell	  activity.	  	  Lastly,	  we	  evaluated	  key	  Tfh	  cytokine	  secretion,	  gene	  expression	  and	  surface	  molecules	  of	  blood	  CXCR5hi	  cells	  in	  order	  to	  establish	  the	  functional	  relationship	  between	  blood	  CXCR5hi	  cells	  and	  GC	  Tfh	  cells.	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THESIS HYPOTHESIS	  
We hypothesized that the phenotype and subset composition of circulating Tfh-like 
CXCR5hi CD4 T cells are altered in human SLE, and that such alterations are associated 
with disease activity and pathological B cell activity, supporting a potential role of Tfh 
cells in the pathogenesis of SLE. 
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METHODS 
Study populations. We analyzed blood samples from two adult cohorts.  The first, from 
the Faculdade de Medicina, Universidade de São Paulo, included 49 SLE patients (46 
female and 3 male; median age 37 years, range 30-48 years; 32 Caucasian, 17 non-
Caucasian), 28 Behçet's disease (BD) patients (22 female and 6 male; median age 48 
years, range 40-56 years; 20 Caucasian, 8 non-Caucasian), and 16 healthy controls (12 
female and 4 male; median age 28 years, range 27-32 years; 13 Caucasian, 3 non-
Caucasian). Their characteristics are shown in Table 1.  We also studied samples from 9 
patients with SLE (8 female and 1 male; median age 40 years, range 26-63 years, 4 
Caucasian, 5non-Caucasian) from Yale-New Haven Hospital (YNHH), with their data 
shown in Figure 4.  SLE patients fulfilled American College of Rheumatology (ACR) 
criteria with disease activity assessed by the SLE Disease Activity Index, whereas BD 
patients met BD criteria set on International Study Group for Behcet’s Disease. Informed 
consent was obtained from all subjects. This study was approved by the institutional 
review committees of the Faculdade de Medicina, Universidade de São Paulo and Yale 
University. 
Flow cytometry.  We isolated peripheral blood mononuclear cells (PBMC) using 
density-gradient centrifugation on Ficoll-Paque with single cell suspensions stained with 
the following antibodies:  Alexa Fluor 700-conjugated CD4, V450-conjugated CD45RA 
and CD27, PE-conjugated PSGL1 and CD4, PE-Cy7-conjugated PD-1, CCR7, and IgD, 
Alexa Fluor 647-conjugated CXCR5 and IL-21, Fluorescein isothiocyanate (FITC)-
conjugated CD62L, APC-Cy7-conjugated CD19, PE-Cy5-conjugated CD38, and 
streptavidin-conjugated APC-Cy7 (all from Becton Dickinson (BD) PharMingen except 
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FITC-conjugated ICOS and PE-CY5 conjugated TCR (eBioscience).  Fluorescence-
labeled cells were collected by multiparameter flow cytometry (LSRFortessa or LSR II; 
BD), with exclusion of doublets by forward and side scatter and analyzed with FlowJo 
software (Tree Star, Ashland, OR).  CD45RA- activated CD4 cells divided to CXCR5hi 
and CXCR5lo cells (Figure 1A, left panel), and circulating Tfh-like cells were identified 
by high expressions of PD-1 and ICOS among CXCR5hi cells (Figure 1B, top right 
quadrants of left and middle panel); the expression of each molecule gated on the basal 
expression of PD-1 (< 0.5%) and ICOS (< 0.5%) on naïve CD45RA+ CD4+ T cells from 
healthy control, and subsequent double positive population of ICOShiPD-1hi (< 0.1%)  
(Figure 1A, right panel). 
Intracellular IL-21 staining.  PBMC stained with surface markers were stimulated with 
PMA (50 ng/ml) and ionomycin (1 g/ml) for first 2 hours then in the presence of golgi 
plug (BD) for last 2 hours.  Cells were fixed with BD CytoFix/CytoPerm and 
permeabilized with BD PERM/ Wash solution, followed by staining with anti IL-21.  
Stained cells were collected by multiparameter flow cytometry (LSR II; BD), with 
exclusion of doublets by forward and side scatter and analyzed with FlowJo software 
(Tree Star, Ashland, OR).  
Statistical analysis.  All data are presented as the mean ± SEM.  The significance of the 
difference between groups was analyzed with one-way ANOVA test, with the 
significance of difference between two groups evaluated by the two-tailed Student’s t 
test.  Spearman correlation coefficient or Pearson correlation coefficient with two-tailed p 
value were determined in the analysis of correlations.  P values less than 0.05 were 
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considered significant.  Data were analyzed with Prism software (version 5.0d for 
Macintosh; GraphPad Software). 
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RESULTS 
Analysis of circulating cells with Tfh surface phenotype in SLE patients.  CXCR5hi 
Tfh cells in secondary lymphoid tissues express PD-1 and ICOS, surface molecules 
central to their B cell helper function in the B cell follicles27.  By contrast, previously 
activated CXCR5hi CD4 T cells in the circulation of normal individuals are typically PD-
1lo and ICOSlo, suggesting that while these cells may be capable of entry in to B cell 
follicles via CXCR5, they may be at a resting state28.  To determine whether blood 
CXC5hi cells carry key Tfh surface phenotype in lupus patients, we examined the 
expression of PD-1 and ICOS in blood samples of 49 SLE patients, 28 BD patients 
(autoimmune disease control), and 16 healthy controls.  We analyzed single CD4+TCRβ+ 
cells, dividing them into naïve (CD45RA+), CXCR5lo (CD45RA-CXCR5lo), and 
CXCR5hi (CD45RA-CXCR5hi) subsets, with additional gating on PD-1 and ICOS 
according to their expression level on the naïve subset (Figure 1A, left panel).  Naïve 
CD45RA+ T cells were CXCR5lo and express basal level of ICOS and PD-1 (Figure 1A, 
right panel).  Consistent with previous reports, majority of blood CXCR5hi cells are PD-
1loICOSlo in healthy donors (Figure 1 B, right panel, representative example; Figure 
1C)28.  Compared with healthy control, there was a significantly higher percentage of 
blood CXCR5hi cells in lupus patients carrying GC Tfh surface phenotype, eg. PD-
1hiICOShi (p < 0.001; Figure 1B, middle panel, blood CXCR5hi cells, representative 
example; Figure 1B, right panel, Tonsil GC Tfh cells; Figure 1C).  In BD patients, there 
was no increased percentage of blood CXCR5hi cells expressing high levels of PD-1 and 
ICOS, suggesting that the presence of circulating Tfh-like CXCR5hiPD-1hiICOShi cells in 
lupus patients is not merely a function of systemic 
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Figure 1. Prevalence of circulating cells with Tfh phenotype in SLE, BD, and healthy 
controls. 
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autoimmunity (Figure 1C).  We also noted a significant increase in the percentage of 
ICOShiPD-1hi cells within the CXCR5lo subset in lupus patients (p < 0.001; Figure 1C).  
However, there was a disassociation of PD-1 and ICOS MFI in the CXCR5lo subset 
(Pearson r = 0.10, p = 0.59; Figure 1D left panel), whereas there was a significant 
correlation of their expression in the CXCR5hi subset (Pearson r = 0.38, p = 0.03; Figure 
1D right panel).  Thus, CXCR5hi subset, but not CXCR5lo subset, resembles GC Tfh cells 
per analysis of surface receptor phenotype. 
 
Figure 2. Expression of Tfh surface receptors in differential subsets of circulating CD4 T 
cells in SLE, BD, and healthy controls.  
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We next asked if a single Tfh-related surface receptor was selectively upregulated 
in lupus patients. ICOS	  is	  a	  co-­‐stimulatory	  molecule	  important	  for	  the	  helper	  function	  of	  Tfh	  cells14.	  	  Previous	  studies	  have	  found	  an	  increase	  in	  circulating	  CD4+ICOShi	  lymphocytes,	  although	  their	  number	  varied	  significantly	  depending	  on	  how	  the	  fraction	  was	  defined	  and	  the	  SLE	  cohort	  studied29-­‐31.	  	  In	  our	  SLE	  cohort,	  we	  did	  not	  find	  a	  significant	  increase	  in	  ICOS	  MFI	  in	  blood	  CXCR5hi	  cells	  (p	  >	  0.05;	  figure	  2A).	  	  PD-­‐1	  is	  another	  key	  Tfh	  surface	  receptor,	  and	  it	  plays	  an	  integral	  role	  in	  the	  formation	  and	  affinity	  of	  plasma	  cells	  in	  the	  context	  of	  GC	  processes16.	  	  Interestingly,	  we	  found	  a	  drastic	  increase	  in	  PD-­‐1	  MFI	  in	  the	  CXCR5hi	  population	  as	  compared	  to	  both	  healthy	  control	  and	  BD	  patients	  (p	  <	  0.001;	  Figure	  2B).	  	  PD-­‐1	  expression	  was	  also	  increased	  in	  the	  CXCR5lo	  subset,	  but	  its	  PD-­‐1	  MFI	  was	  significantly	  lower	  than	  those	  of	  CXCR5hi	  subset	  (Figure	  2B).	  
Taken together, we have found a significant expansion of blood CXCR5hi cells 
that are PD-1hiICOShi, akin to GC Tfh cells, in lupus patients.  PD-1, a molecule known 
for its role in GC B cell survival, but not ICOS, was selectively upregulated in the 
CXCR5hi subset in lupus compared to healthy controls. 
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Figure 3.  PD-1 expression on circulating CXCR5hi subset correlates with Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) and expansion of circulating 
plasmablasts. 
	   17	  
Correlation between PD-1 expression on blood CXCR5hi cells and disease activity in 
SLE.  We next asked if altered phenotype of blood CXCR5hi cells, the circulating 
counterpart of Tfh cells, correlated with SLE disease activity.  We first examined the 
relationship between the expansion of CXCR5hiPD-1hiICOShi cells and SLE disease 
activity index (SLEDAI); however, we did not find a significant correlation between the 
two variables (Spearman’s r = 0.26, p = 0.19; data not shown).  Similarly, we did not find 
significant correlations between the percentages of CXCR5hiPD-1hiICOShi cells and 
organ involvement, as well as aberrant B cells activation.  In addition, we did not find a 
correlation between the percentage of CXCR5hi cells in CD4 T cells and SLEDAI 
(Spearman’s r = -0.21, p = 0.28; Figure 3A).   
 We then asked whether differential expression of key Tfh surface receptors on 
blood CXCR5hi cells is correlated with disease activity in human lupus.  In the cohort of 
SLE patients with active disease, we found a significant correlation between PD-1 MFI in 
blood CXCR5hi subset and SLEDAI scores (Spearman r = 0.43, p = 0.03; Figure 3B).  
Elevated PD-1 may merely reflect T cells activation32 that is common in active SLE; 
however, this did not appear to be the case, as ICOS, a marker of activated T cells, and 
the patients’ SLEDAI was not correlated (Spearman r = 0.16, p = 0.52; Figure 3C).  
Moreover, there was no relationship between the percentage of activated CD45RA- CD4 
T cells and SLEDAI (data not shown). 
Given the association between PD-1 MFI on CXCR5hi cells and disease activity, 
we also asked if the former was linked to organ involvement.  In patients with concurrent 
proteinuria and hematuria, compared those without, we found an increase in PD-1 MFI 
on CXCR5hi cells (1911 vs. 1199, respectively; p = 0.02), as we did for patients with 
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ongoing pyuria (2590 vs. 1200; p = 0.0007).  By contrast, apart from serositits (1551 vs. 
1087, p = 0.007), PD-1 did not correlate with past organ injury, including skin, joint, 
kidney, CNS, and vasculature.  These results in aggregate indicated that the PD-1 MFI on 
CXCR5hi cells correlated with disease activity, including renal inflammation.  Consistent 
with this theme, we found that PD-1 MFI on the CXCR5hi CD4 T cell subset was 
increased in patients with elevated anti-dsDNA antibody titers, when compared to 
patients without such autoantibodies (1891 vs. 1169, respectively; p = 0.004), and 
elevated hypocomplementemic patients (1862 vs. 1173, p = 0.006), with the latter 
presumably reflecting consumption upon engagement by autoantibody-autoantigen 
immune complexes as a feature of active SLE3. 
Association between PD-1 MFI and expansion of circulating plasmablasts.  The 
correlation between PD-1 on circulating CD4+CXCR5hi T cells and anti-dsDNA antibody 
titers and presumed complement consumption suggested that elevated expression of this 
protein might also be correlated with aberrant B cell activation.  PD-1 is also critical, 
among other proteins, for Tfh-directed GC maturation and plasma cell genesis16.  We 
therefore purified lymphocytes from patients and controls, staining them with CD19, IgD, 
and CD38 to assess the pool of the IgD-CD38hi plasmablasts33.  Consistent with previous 
reports34, we found an increase in the percentage of circulating plasmablasts in SLE 
patients compared to healthy controls (Figure 3D).  We also found that the PD-1 MFI 
among CXCR5hi cells positively correlated with the expansion of plasmablast in lupus 
patients (Figure 3E, left panel).  Of note, the percentage of plasmablasts was similar 
between SLE patients regardless of treatment (Figure 3E, right panel). 
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Analysis of circulating CXCR5hiPD-1hi cells in human SLE patients.  Since the 
presence circulating CXCR5hi cells carrying high levels of PD-1 strongly correlated with 
disease activity and pathological B cell activity in lupus, we next asked how the 
CXCR5hiPD-1hi cells are differ from the CXCR5hiPD-1lo cells, and whether they exhibit 
key characteristics of GC Tfh cells.  IL-21 is a key cytokine secreted by Tfh cells, leading 
to differentiation, proliferation, isotype switching of B cells17,18.  We therefore examined 
the presence of IL21-producing cells in circulating CXCR5hiPD-1hi CD4 T cells of lupus 
patients.  We sought CD4+CD45RA-CXCR5hi cells and divided them into PD-1lo and 
PD-1hi subset to measure the percentage of IL-21 producing cells in each population 
(Figure 4A, left panel; representative example).  In lupus patients, we found a significant 
higher proportion of IL21+ cells in the CXCR5hiPD-1hi subset compared to CXCR5hiPD-
1lo subset (p = 0.02; Figure 4A, right panel).  The secretion of IL21 suggests that blood 
CXCR5hiPD-1hi cells in lupus patients are functionally related to bona fide Tfh cells in 
their capability to provide B cell-help signals.   
Previously, circulating CXCR5hi CD4 T cells in healthy donors were found to 
have a central memory phenotype, with high expression level of CCR7, which is required 
for cell entry into secondary lymphoid organs28.  In contrast, GC Tfh cells down-regulate 
CCR7 in order to achieve proper follicular positioning.  We therefore asked whether 
blood CXCR5hiPD-1hi cells in lupus carried a central memory phenotype28 or a GC Tfh-
like phenotype by analyzing their level of CCR7 expression.  We compared CCR7 MFI 
of CXCR5hiPD-1hi cells and CXCR5hiPD-1lo cells in the form of its relative expression to 
CCR7 MFI on naïve CD45RA+CD4 T cells  
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Figure 4. Functional and phenotypic analysis of circulating CXCR5hiPD-1hi cells. 
	   21	  
(representative sample, figure 4B, left panel).  Interestingly, we found a significant lower 
CCR7 expression in CXCR5hiPD-1hi cells when compared to CXCR5hiPD-1lo cells.  
Thus, blood CXCR5hiPD-1hi cells do not resemble the previously described circulating 
CXCR5hi central memory population.  Instead, it more resembles active Tfh cells in 
secondary lymphoid organ based on memory marker analysis. 
Bcl-6 is the key transcriptional factor that drives Tfh formation35-37.  It is highly 
expressed in GC Tfh cells38,39.  In addition, its overexpression is sufficient to upregulate 
CXCR5, PD-1, ICOS, and downregulate CCR7 in vitro and in vivo 35,36.  Therefore, we 
assessed Bcl-6 expression in blood CXCR5hiPD-1hi cells of lupus sample as compared to 
naïve CD45RA+ CD4 T cells and CXCRhiPD-1hiICOShi Tfh cells from Tonsils of a non-
lupus patient.  We found that blood CXCR5hiPD-1hi cells in lupus express the basal level 
of bcl-6 at a level similar to that of naïve CD4 T cells (representative sample, Figure 4C). 
Taken together, our data supports a model in which follicular helper T cell 
phenotype is altered in human systemic lupus erythematosus (Figure 5).  In such model, 
presentation of autoantigen by dendritic cells (DC) to T cells leads to the differentiation 
of T helper (Th) cells and follicular helper T precursors (pre-Tfh) (1, Figure 5).  Tfh-
destined cells migrate to border of T-cell zones and B-cell follicles, where they contact 
autoantigen-activated B cells (2, Figure 5).  Subsequent migration of both subsets deeper 
into the follicle leads to germinal center (GC) formation (3, Figure 5).  GC Tfh cells are 
notable for high CXCR5, PD-1, and Bcl6 expression, as well as production of IL-21.  In  
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Figure 5. Model of altered follicular helper T cell phenotype in systemic lupus 
erythematosus. 
 
the GC, Tfh cells promote class switching and affinity selection of B cells via secretion of 
cytokine (eg. IL-21) and expression of cell bound molecules (eg. PD-1).  The result is the 
production of high-affinity autoantibody-secreting plasma cells, leading to pathology and 
disease activity (4, Figure 5).  In parallel, there is an expansion of Tfh-like cells in the 
peripheral blood (5, Figure 5).  Akin to Tfh cells, these Tfh-like cells also express high 
levels of CXCR5, PD-1, and are enriched with IL-21 producers.  The presence of 
CXCR5hiPD-1hi Tfh-like cells in blood is associated with disease activity, plasmablast 
expansion, and autoantibody production.  Unlike GC Tfh cells, circulating Tfh-like cells 
have low levels of Bcl6, indicating that they may have relocated to the periphery pre- or 
post-germinal center reaction.  Importantly, these circulating Tfh-like cells express low 
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level of CCR7, which differentiate them from previously described circulating central 
memory T cells with high level of CXCR528 (6, figure 5). 
Differential composition of Tfh subsets in human SLE.  Recently, human blood 
CXCR5hi CD4 T cells was found to consist of three subsets (Th1, Th2, and Th17), based 
on their cytokine production and chemokine receptor profile25.  Notably, Th2 and Th17, 
but not Th1, CXCR5hi CD4 T cells secrete IL-21 and promote differential antibody 
secretion by naïve B cells in vitro25.  Consistent with previous findings, we found that a 
portion, but not all, of CXCR5hi CD4 T cells were IL-21 producers (Figure 4A).   We 
therefore asked if there is another dimension of Tfh dysregulation in human SLE, 
namely, if the blood CXCR5hi subset composition was different among lupus patients and 
our two control groups.  We gated on circulating CD4+TCRβ+CD45RA-CXCR5hi 
lymphocytes, using chemokine receptors (CXCR3, CCR4, and CCR6) to identify subsets, 
with Th1 cells defined as CXCR3hiCCR4-CCR6lo, Th2 as CXCR3loCCR4hiCCR6lo, and 
the Th17 subset as CXCR3loCCR4loCCR6hi (Figure 6A)25,40.  Where as lupus patients had 
a reduction of Th1 CXCR5hi cells compared to healthy donors, and a decrease in the 
Th17 subset compared to BD patients (Figure 6B, left and right panel, respectively), we 
found expansion of the CXCR5hi Th2 subset compared to BD patients, with a trend 
toward an increase compared to healthy controls (Figure 6B, middle panel).  Consistent 
with the latter finding was the positive association between the frequency of CXCR5hi 
Th2 cells and patients’ SLEDAI, an association that is not clearly observed with the Th1 
and Th17 populations (Figure 6C). 
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Figure 6. Composition of circulating CXCR5hi subsets and its relationship with SLE 
disease activity.
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DISCUSSION 
 
SLE is an autoimmune disease characterized by the production of autoantibodies.  
The pathogenic antibodies in SLE are isotype-switched, suggesting the involvement Tfh 
cells in the GC response8.  However, the involvement of Tfh cells in disease activity of 
human SLE remains unclear.  Blood CXCR5hi cells are attractive biomarkers to study 
human Tfh dysregulation because they exhibit key functional and physical characteristics 
of Tfh cells and have been proposed to be their circulating counterparts25.  In addition, 
expansion of blood CXCR5hiPD-1hi and CXCR5hiICOShi cells have been found in a 
subset of SLE patients with severe end-organ involvement26. 
CXCR5hi Tfh cells in secondary lymphoid tissues express high levels of PD-1 and 
ICOS, surface molecules central to their B cell helper function27.  In contrast, blood 
CXCR5hi CD4 T cells in healthy individuals are PD-1loICOSlo, suggesting that while they 
are capable of entry into B cell follicles via CXCR5, they may not be actively carrying 
out Tfh functions28.  Here, we report a significant increase of CXCR5hiPD-1hiICOShi cells 
in SLE patients as compared to healthy controls. Such	  expansion	  was	  not	  seen	  in	  Behçet's	  disease,	  demonstrating	  that	  it	  was	  not	  merely	  a	  function	  of	  systemic	  inflammatory	  disorder,	  but	  a	  distinctive	  phenotype	  in	  human	  SLE.	  	  The	  presence	  of	  such	  circulating	  Tfh-­‐like	  cells	  likely	  reflect	  germinal	  center	  dysfunction,	  a	  hallmark	  of	  murine	  lupus19-­‐21,	  and	  one	  likely	  present	  in	  human	  SLE,	  as	  evidenced	  by	  studies	  demonstrating	  abnormal	  GC	  B	  cell	  selection41	  and	  circulating	  GC	  B	  cells	  in	  patients	  with	  active	  disease42-­‐44. 
We have found that the combination of high CXCR5 and high PD-1 expression 
effectively identifies circulating cells resembling pre- or post-GC Tfh cells in SLE 
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patients.  High expression of CXCR5 implies that these cells are capable of being 
retained near B cells follicles in response to CXCL13 much like Tfh cells13,27.  High 
expression of PD-1 suggests that these cells have the capability to regulate GC B cell 
survival16.  These cells also express relatively higher amounts of ICOS as we found a 
significant positive correlation between ICOS and PD-1 expression in CXCR5hi CD4 T 
cells.  The ICOS-ICOSL interaction between T cells and B cells has been shown to be 
central in T-dependent antibody response, Ig switching, and GC formation45-47.  
Importantly, blood CXCR5hiPD-1hi cells are enriched with IL-21 producers when 
compared to CXCR5hiPD-1lo cells.  IL-21 is a hallmark cytokine produced by Tfh cells, 
and is important for the differentiation, proliferation, isotype-switching of B cells17,18,48.   
Thus, blood CXCR5hiPD-1hi cells strongly resemble Tfh cells based on phenotypic and 
functional analysis.  We also found that circulating CXCR5hiPD-1hi cells expressed lower 
level of Bcl-6 when compared to GC Tfh cells39,49.  This result is consistent with previous 
findings in blood CXCR5hiICOShi Tfh-like cells of lupus patients26.  Our result implies 
that blood CXCR5hiPD-1hi cells may be pre-GC Tfh cells.  Alternatively, Bcl-6 may have 
been down-regulated post-GC reaction in a manner analogous to decreased Bcl-6 
expression level in post-GC B cells50, suggesting that these cells are post-GC Tfh cells 
that have been dislocated into the periphery.  The presence of these pre- or post-GC Tfh-
like cells in the periphery strongly suggest that there is GC Tfh expansion or dysfunction 
in human SLE – a consistent finding in multiple animal models of SLE19-21.  In the future, 
the relationship between blood CXCR5hiPD-1hi cells and GC Tfh cells may be further 
clarified using, for instance, an IL-21 reporter mice system51.   
	   27	  
Importantly, the circulating CXCR5hiPD-1hi population in human SLE is distinct 
from the previously described blood CXCR5hi central memory T (Tcm) cells28.  We 
found that blood CXCR5hiPD-1hi cells expressed low levels of CCR7, a key chemokine 
receptor of memory T cells that control migration to secondary lymphoid organs52.  Thus, 
they did not resemble CXCR5hi Tcm cells phenotypically.  The combination of high 
CXCR5 and low CCR7 also implies that these cells are more similar to Tfh cells, rather 
then Tcm cells, in their localization capability.  This is because while CXCR5 expression 
is sufficient for localization to the T-B border, CXCR5 expression is not sufficient for 
Tfh cells to localize inside follicles53.  In fact, high levels of CCR7 expression can block 
T cell migration to the B cell zone54.  Thus, Tfh cells needs to downregulate CCR7 in 
order to migrate to T-B boundary region55, a phenotype consistent with the circulating 
CXCR5hiPD-1hi cells in human SLE. 
We have found that PD-1 MFI in blood CXCR5hi cells correlated significant with 
disease activity in SLE patients with active disease.  PD-1 MFI in CXCR5hi cells is a 
composite value reflecting the shift from CXCR5hiPD-1lo Tcm cells to CXCR5hiPD-1hi 
pre- or post-GC Tfh cells.  It also reflects PD-1 expression level in CXCR5hiPD-1hi cells.  
This raises the possibility that both the expansion of Tfh compartment and the degree of 
PD-1 expression on Tfh cells may contribute to SLE disease activity and thus play a role 
in lupus pathology.   
With regards to the expansion of Tfh cells, such	  phenotype	  has	  already	  been	  causally	  linked	  to	  the	  abundance	  of	  GCs,	  production	  of	  autoantibodies,	  and	  end-­‐organ	  damage	  in	  a	  mouse	  model	  of	  SLE21.	  	  The	  expansion	  of	  circulating	  Tfh-­‐like	  cells	  has	  also	  been	  associated	  with	  severity	  of	  end	  organ	  damage	  in	  human	  SLE26.	  	  Our	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results	  show	  for	  the	  first	  time	  that	  such	  phenotype	  is	  also	  associated	  with	  disease	  activity.	  	  A previous report has found no relationship between SLE disease activity and 
the expansion of Tfh-like CXCR5hiICOShi cells26.  The two studies differ in the use of 
PD-1 vs. ICOS to define blood Tfh-like cells.  Here, we found that PD-1, but not ICOS, 
was significantly upregulated in CXCR5hi cells of SLE patients when compared to 
healthy controls and thus served as a better marker to differentiate Tfh-like cells from 
CXC5hi Tcm cells.  In concordance, previous studies have found that the number of 
CD4+ICOShi cells varied significantly depending on how the fraction was defined and the 
SLE cohort studied29-31.  Furthermore, consistent	  with	  the	  correlation	  between	  Tfh	  dysregualtion	  and	  SLE	  disease	  activity,	  we	  have	  found	  strong	  association	  between	  Tfh	  dysregulation,	  expansion	  of	  circulating	  plasmablast,	  production	  of	  autoantibodies,	  and	  ongoing	  kidney	  injury.	  	  Together,	  these	  findings	  suggest	  that	  expansion	  of	  Tfh	  cells	  are	  intimately	  involved	  in	  SLE	  disease	  flares,	  making	  them	  possible	  targets	  for	  monitoring	  or	  treating	  an	  increase	  in	  disease	  activity.	  	  Further	  validation	  with	  longitudinal	  studies	  will	  clarify	  their	  potential	  usefulness	  as	  biomarkers	  of	  disease	  activity	  and	  as	  a	  therapeutic	  target.	  Our	  findings	  suggest	  that	  the	  degree	  of	  PD-­‐1	  expression	  on	  Tfh	  cells	  may	  also	  contribute	  to	  GC	  dysfunction	  and	  SLE	  disease	  activity.	  	  Indeed, PD-1 expression on 
Tfh cells appears to play an important role in regulating GC cell survival16.  Classically, 
PD-1 is known as an inhibitory receptor associated with CD8 T cell exhaustion during 
chronic viral infection15,56,57.  However, PD-1 is highly expressed on GC Tfh cells54,58,59, 
and GC B cells express PD-L1 and elevated PD-L216.  Interestingly, mice deficient in 
PD-1 or PD-1 ligands had worsened B cell response, with increased GC cell death and 
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decreased Tfh cell cytokine production, such as IL-4 and IL2116.  It is important to note 
that PD-1 can provide bidrectional signaling through PD1-PDL1 or PDL2 complexes15, 
and PD-1 may provide direct inductive signals from GC Tfh to GC B cells or affect 
duration of T-B conjugates55,60.  Though the loss of function of PD-1 has been studied in 
the context of GC reaction16, conducting gain of function study in the future may help 
dissecting the mechanism between elevated PD-1 expression on Tfh-like cells and SLE 
disease activity.  Of note, the upregulation of PD-1 on circulating CD4 T cells in SLE 
patients did not appear to be a reflection of generalized T cell activation as we did not 
find a correlation between the percentage of activated (CD45RA-) CD4 T cells and PD-1 
expression (data not shown).  Elevated PD-1 also did not appear to be merely a function 
of systemic autoimmunity as there was no alteration of PD-1 expression in BD patients.  
Multiple factors may have contributed to elevated PD-1 expression in Tfh-like cells.  
First, there is increased IL-21 secretion in human SLE61, which is able to induce PD-1 
expression62.  Second, there is increased type 1 interferon signal in SLE63, which can 
enhance humoral immunity and promote isotype switching in vivo, suggesting the 
involvement of Tfh cells. IFN regulated-element has also been found upstream of PD-1 
gene in mice and enhances PD-1 expression in CD4 T cells64.  Lastly, elevated Tfh PD-1 
may also be a reflection of repeated TCR stimulation via increased T-B contact in SLE15. 
We showed that there is an altered composition of circulating Tfh subsets in SLE.  
In both SLE and BD patients, there was an underrepresentation of CXCR5hi Th1 cells 
compared to healthy controls.  A similar observation has been reported in patients with 
juvenile dermatomyositis25.  As previously demonstrated, CXCR5hi Th1 cells lacked B 
helper activity25, and therefore the expansion of non-Th1 Tfh cells may be a significant 
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contributing factor to pathogenic autoantibody production in SLE.  Interestingly, there 
was differential expansion of CXCR5hi subsets in SLE vs. BD patients.  SLE patients had 
significantly higher CXCR5hi Th2 cells compared to BD, while BD patients had 
significantly higher CXCR5hi Th17 cells compared to SLE.  While both Th2 and Th17 
Tfh subtypes help B cells and induce Ig switch, Th2 subset is better at inducing IgE 
production while Th17 subset is better at inducing IgA production25.  Thus, the 
differential expansion of functional Tfh subset may shape the characteristics of antibody 
response in a disease specific manner. 
In conclusion, our data show an expansion of circulating pre- or post-GC Tfh cells 
in human SLE.  The expansion of Tfh compartment, along with elevated expression of 
PD-1, a key regulator of GC cell survival, is strongly associated with SLE disease 
activity.  Thus, Tfh population may be an attractive candidate for the monitoring and 
treatment of SLE disease flares.  We have also described, for the first time, the altered 
composition of Tfh subsets in SLE and revealed another dimension of Tfh dysregulation 
previously not appreciated.  These data provide a basis to better elucidate the dynamics of 
pathological Tfh activity in human SLE. 
	   31	  
REFERENCES 
1. Tsokos GC. Systemic lupus erythematosus. The New England journal of medicine 
2011;365:2110-21. 
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification 
of systemic lupus erythematosus. Arthritis and rheumatism 1982;25:1271-7. 
3. Rahman A, Isenberg DA. Systemic lupus erythematosus. The New England 
journal of medicine 2008;358:929-39. 
4. MacLennan IC. Germinal centers. Annual review of immunology 1994;12:117-
39. 
5. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular 
dynamics. Immunity 2007;27:190-202. 
6. Mietzner B, Tsuiji M, Scheid J, et al. Autoreactive IgG memory antibodies in 
patients with systemic lupus erythematosus arise from nonreactive and polyreactive 
precursors. Proceedings of the National Academy of Sciences of the United States of 
America 2008;105:9727-32. 
7. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert 
MG. The role of clonal selection and somatic mutation in autoimmunity. Nature 
1987;328:805-11. 
8. Ravirajan CT, Rahman MA, Papadaki L, et al. Genetic, structural and functional 
properties of an IgG DNA-binding monoclonal antibody from a lupus patient with 
nephritis. European journal of immunology 1998;28:339-50. 
9. Luzina IG, Atamas SP, Storrer CE, et al. Spontaneous formation of germinal 
centers in autoimmune mice. Journal of leukocyte biology 2001;70:578-84. 
	   32	  
10. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in 
systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. 
The Journal of clinical investigation 2003;112:1506-20. 
11. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. 
Follicular helper T cells: lineage and location. Immunity 2009;30:324-35. 
12. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC 
chemokine receptor 5, localize to B cell follicles, and support immunoglobulin 
production. The Journal of experimental medicine 2000;192:1545-52. 
13. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC. 
Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-
localized subset of CXCR5+ T cells. The Journal of experimental medicine 
2001;193:1373-81. 
14. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and 
dysregulated immune responses. Annual review of immunology 2008;26:741-66. 
15. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance 
and immunity. Annual review of immunology 2008;26:677-704. 
16. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, 
Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and 
affinity of long-lived plasma cells. Nature immunology 2010;11:535-42. 
17. Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human 
naive and memory B cells into antibody-secreting plasma cells. J Immunol 
2005;175:7867-79. 
	   33	  
18. Pene J, Gauchat JF, Lecart S, et al. Cutting edge: IL-21 is a switch factor for the 
production of IgG1 and IgG3 by human B cells. J Immunol 2004;172:5154-7. 
19. Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation accelerates systemic 
autoimmunity in murine lupus. Proceedings of the National Academy of Sciences of the 
United States of America 2006;103:9970-5. 
20. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family 
member required to repress follicular helper T cells and autoimmunity. Nature 
2005;435:452-8. 
21. Linterman MA, Rigby RJ, Wong RK, et al. Follicular helper T cells are required 
for systemic autoimmunity. The Journal of experimental medicine 2009;206:561-76. 
22. Vinuesa CG, Cook MC. Blood relatives of follicular helper T cells. Immunity 
2011;34:10-2. 
23. Bossaller L, Burger J, Draeger R, et al. ICOS deficiency is associated with a 
severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol 2006;177:4927-
32. 
24. Schaerli P, Loetscher P, Moser B. Cutting edge: induction of follicular homing 
precedes effector Th cell development. J Immunol 2001;167:6082-6. 
25. Morita R, Schmitt N, Bentebibel SE, et al. Human blood CXCR5(+)CD4(+) T 
cells are counterparts of T follicular cells and contain specific subsets that differentially 
support antibody secretion. Immunity 2011;34:108-21. 
26. Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells 
resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe 
systemic lupus erythematosus. Arthritis and rheumatism 2010;62:234-44. 
	   34	  
27. Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. 
Nature reviews Rheumatology 2012;8:337-47. 
28. Chevalier N, Jarrossay D, Ho E, et al. CXCR5 expressing human central memory 
CD4 T cells and their relevance for humoral immune responses. J Immunol 
2011;186:5556-68. 
29. Hutloff A, Buchner K, Reiter K, et al. Involvement of inducible costimulator in 
the exaggerated memory B cell and plasma cell generation in systemic lupus 
erythematosus. Arthritis and rheumatism 2004;50:3211-20. 
30. Kawamoto M, Harigai M, Hara M, et al. Expression and function of inducible co-
stimulator in patients with systemic lupus erythematosus: possible involvement in 
excessive interferon-gamma and anti-double-stranded DNA antibody production. 
Arthritis research & therapy 2006;8:R62. 
31. Yang JH, Zhang J, Cai Q, et al. Expression and function of inducible costimulator 
on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology 
2005;44:1245-54. 
32. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. 
Current opinion in immunology 2007;19:309-14. 
33. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification 
and characterization of circulating human transitional B cells. Blood 2005;105:4390-8. 
34. Hostmann A, Jacobi AM, Mei H, Hiepe F, Dorner T. Peripheral B cell 
abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008;17:1064-
9. 
	   35	  
35. Johnston RJ, Poholek AC, DiToro D, et al. Bcl6 and Blimp-1 are reciprocal and 
antagonistic regulators of T follicular helper cell differentiation. Science 2009;325:1006-
10. 
36. Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T 
follicular helper cells. Science 2009;325:1001-5. 
37. Yu D, Rao S, Tsai LM, et al. The transcriptional repressor Bcl-6 directs T 
follicular helper cell lineage commitment. Immunity 2009;31:457-68. 
38. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene 
expression program of human germinal center T helper cells. Blood 2004;104:1952-60. 
39. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a 
distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that 
provide help for B cells. J Immunol 2004;173:68-78. 
40. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine 
receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J 
Immunol 1998;161:5111-5. 
41. Cappione A, 3rd, Anolik JH, Pugh-Bernard A, et al. Germinal center exclusion of 
autoreactive B cells is defective in human systemic lupus erythematosus. The Journal of 
clinical investigation 2005;115:3205-16. 
42. Kuchen S, Robbins R, Sims GP, et al. Essential role of IL-21 in B cell activation, 
expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J 
Immunol 2007;179:5886-96. 
	   36	  
43. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased 
frequency of pre-germinal center B cells and plasma cell precursors in the blood of 
children with systemic lupus erythematosus. J Immunol 2001;167:2361-9. 
44. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in 
patients with systemic lupus erythematosus. Journal of immunological methods 
2011;363:187-97. 
45. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated 
antibody class switching. Nature 2001;409:102-5. 
46. Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is 
associated with adult-onset common variable immunodeficiency. Nature immunology 
2003;4:261-8. 
47. Mak TW, Shahinian A, Yoshinaga SK, et al. Costimulation through the inducible 
costimulator ligand is essential for both T helper and B cell functions in T cell-dependent 
B cell responses. Nature immunology 2003;4:765-72. 
48. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and 
amplification of proliferative responses following stimulation with IL-21. J Immunol 
2006;177:5236-47. 
49. Rasheed AU, Rahn HP, Sallusto F, Lipp M, Muller G. Follicular B helper T cell 
activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 
expression. European journal of immunology 2006;36:1892-903. 
50. Kuo TC, Shaffer AL, Haddad J, Jr., Choi YS, Staudt LM, Calame K. Repression 
of BCL-6 is required for the formation of human memory B cells in vitro. The Journal of 
experimental medicine 2007;204:819-30. 
	   37	  
51. Luthje K, Kallies A, Shimohakamada Y, et al. The development and fate of 
follicular helper T cells defined by an IL-21 reporter mouse. Nature immunology 
2012;13:491-8. 
52. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune 
response by establishing functional microenvironments in secondary lymphoid organs. 
Cell 1999;99:23-33. 
53. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster 
JG. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram 
their response to lymphoid chemokines. The Journal of experimental medicine 
1999;190:1123-34. 
54. Haynes NM, Allen CD, Lesley R, Ansel KM, Killeen N, Cyster JG. Role of 
CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell 
death gene-1high germinal center-associated subpopulation. J Immunol 2007;179:5099-
108. 
55. Crotty S. Follicular helper CD4 T cells (TFH). Annual review of immunology 
2011;29:621-63. 
56. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T 
cells during chronic viral infection. Nature 2006;439:682-7. 
57. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell 
exhaustion by multiple inhibitory receptors during chronic viral infection. Nature 
immunology 2009;10:29-37. 
	   38	  
58. Yusuf I, Kageyama R, Monticelli L, et al. Germinal center T follicular helper cell 
IL-4 production is dependent on signaling lymphocytic activation molecule receptor 
(CD150). J Immunol 2010;185:190-202. 
59. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-
1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell 
lymphoma. The American journal of surgical pathology 2006;30:802-10. 
60. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 
promote tolerance by blocking the TCR-induced stop signal. Nature immunology 
2009;10:1185-92. 
61. Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates 
with T cell and B cell subset alterations in systemic lupus erythematosus. The Journal of 
rheumatology 2012;39:1819-28. 
62. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines 
IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its 
ligands. J Immunol 2008;181:6738-46. 
63. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon 
system in systemic lupus erythematosus correlates with disease activity but not with 
antiretroviral antibodies. Lupus 2000;9:664-71. 
64. Terawaki S, Chikuma S, Shibayama S, et al. IFN-alpha directly promotes 
programmed cell death-1 transcription and limits the duration of T cell-mediated 
immunity. J Immunol 2011;186:2772-9. 
 
	   39	  
FIGURE LEGENDS 
 
Figure 1.  Prevalence of circulating cells with Tfh phenotype (CXCR5hiICOShiPD-1hi) in 
blood samples of healthy controls (H; n = 16), patients with Behçet's disease (BD; n = 
28), and patients with systemic lupus erythematosus (SLE; n = 49).  A, Representative 
fluorescence-activated cell sorter (FACS) analysis of circulating lymphocytes, gated on 
viable CD4+TCRβ+ cells (left panel), plus CD45RA+ cells (naïve subset), CD45RA-
CXCR5lo cells (CXCR5lo subset), and CD45RA-CXCR5hi cells (CXCR5hi subset).  
Representative expression of ICOS and PD-1 in naïve subset; value in naïve subset gate 
(ICOShiPD-1hi [black box]) is the percentage of viable lymphocytes (right panel).  B, 
Representative FACS analysis of ICOS and PD-1 expression in the CXCR5hi subset from 
healthy peripheral blood mononuclear cells (PBMC; left panel), SLE PBMC (middle 
panel), and Tonsil (right panel).  Values in the compartments (black box) are the 
percentages of ICOShiPD-1hi cells.  C, Expansion of ICOShiPD-1hi cells in CXCR5hi and 
CXCR5lo subset in SLE patients, but not in BD patients or healthy controls.  Statistical 
analysis was performed using One-way ANOVA (*** p < 0.001).  D, Correlation 
between PD-1 and ICOS expression (mean fluorescence intensity; MFI) in CXCR5hi 
(Pearson r = 0.38, p = 0.03), but not CXCR5lo (Pearson r = 0.10, p = 0.59) subset.  Data 
points represent individual subjects; horizontal lines represent the mean value with 
standard error of the mean. 
Figure 2.  Expression of follicular helper T cell (Tfh) surface receptors in circulating 
CD4+ lymphocytes of healthy controls (H), patients with Behçet's disease (BD), and 
patients with systemic lupus erythematosus (SLE).  A, similar ICOS expression (MFI) in 
CXCR5hi and CXCR5lo subset in SLE patients as compared to healthy control.  B, 
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elevated PD-1 expression (MFI) in CXCR5hi and CXCR5lo subset in SLE patients as 
compared to healthy control and BD patients.  Data points represent individual subjects; 
horizontal lines represent the mean value with standard error of the mean.  Statistical 
analysis was performed using One-way ANOVA.  (* p < 0.05;  ** p < 0.01; *** p < 
0.001; n.s. no significance).  See figure 1 for additional definitions. 
Figure 3.  PD-1 expression on circulating CXCR5hi subset correlates with Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) and expansion of circulating 
plasmablasts.  A, No association between percentages of activated CXCR5hi subset in 
circulating CD4+ T cells and SLEDAI (Spearman r = - 0.21, p = 0.28) in systemic lupus 
erythematosus (SLE) patients with active disease.  B, Significant correlation between PD-
1 MFI in circulating CXCR5hi subset and clinical activity as measured by SLEDAI 
(Spearman r = 0.43, p = 0.03) in SLE patients with active disease.  C, No association 
between ICOS MFI in CXCR5hi subset and SLEDAI (Spearman r = 0.16; p = 0.52) in 
SLE patients with active disease.  D, expansion of circulating plasmablast (CD19+IgD-
CD38+) in SLE patients as compared to Behçet's disease (BD) and healthy control (H).  
Statistical analysis was performed using One-way ANOVA (* p < 0.05).  E, Correlation 
between percentage of circulating plasmablasts and PD-1 MFI in blood activated 
CXCR5hi subset (CD45RA-CXCR5hi) in SLE patients (Spearman r = 034; p = 0.02; left 
panel).  Percentage of circulating plasmablasts in the presence or absence of prednisone, 
antimalarial, and azathioprine treatments in the SLE patient cohort.  Statistical analysis 
was performed using Student’s t test (n.s. = no significance).  Data points represent 
individual subjects; horizontal lines represent the mean values with standard error of the 
mean. 
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Figure 4.  Functional and phenotypic analysis of circulating CXCR5hiPD-1hi cells.  A,  
Representative FACS analysis of intracellular IL-21 staining in circulating CXCR5hiPD-
1lo cells and CXCR5hiPD-1hi cells; values represent percentages of IL-21+ cells (left 
panel).  Increased percentage of IL-21+ cells in circulating CXCR5hi-PD-1hi population as 
compared to CXCR5hiPD-1lo population (p = 0.02; right panel).  B, Representative FACS 
analysis of CCR7 expression in circulating naïve, CXCR5hiPD-1lo, and CXCR5hiPD-1hi 
subsets; gating of PD-1hi and PD-1lo subset is based on PD-1 expression on circulating 
naïve subset (left panel).  Significant decrease in CCR7 expression in CXCR5hiPD-1hi 
cells as compared to CXCR5hiPD-1lo cells (p = 0.03).  CCR7 expression is represented as 
relative CCR7 MFI to that of circulating naïve subset (right panel).  C, Representative 
histogram showing the expression of Bcl6 in SLE circulating CXCR5hiPD-1hi cells, 
Tonsil naïve cells (CD4+TCRβ+CD45RA+), and Tonsil follicular helper T cells (Tfh; 
CD4+TCRβ+CD45RA-CXCR5hiPD-1hi). Statistical analysis was performed using 
Student’s t test. 
Figure 5.  Model of altered follicular helper T cell phenotype in systemic lupus 
erythematosus.  Presentation of autoantigen by dendritic cells (DC) to T cells leads to the 
differentiation of T helper (Th) cells and follicular helper T precursors (preTfh).  Tfh-
destined cells migrate to border of T-cell zones and B-cell follicles, where they contact 
autoantigen-activated B cells.  Subsequent migration of both subsets deeper into the 
follicle leads to germinal center (GC) formation.  GC Tfh cells are notable for high 
CXCR5, PD-1, and Bcl6 expression, as well as production of IL-21.  In the GC, Tfh cells 
promote class switching and affinity selection of B cells via secretion of cytokines (eg. 
IL-21) and expression of cell bound molecules (eg. PD-1).  The result is the production of 
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high-affinity autoantibody-secreting plasma cells, leading to pathology and disease 
activity.  In parallel, there is an expansion of Tfh-like cells in the peripheral blood.   Akin 
to Tfh cells, these Tfh-like cells also express high levels of CXCR5 and PD-1, and are 
enriched with IL-21 producers.  High PD-1 expression in blood Tfh-like cells is 
associated with disease activity, plasmablast expansion, and autoantibody production.  
Unlike GC Tfh cells, circulating Tfh-like cells have low levels of Bcl6, indicating that 
they may have relocated to the periphery pre- or post-germinal center reaction.  
Importantly, these circulating Tfh-like cells express low levels of CCR7, which 
differentiate them from previously described central memory T cells with high level of 
CXCR5.  
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TABLES 
 
 
Table 1. Study population characteristics. 
 
 
